Nohla is a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases. The company’s lead product, NLA101, is a universal donor, ex vivo expanded hematopoietic stem and progenitor cell product that provides bridging hematopoiesis in vivo, rapidly generating mature and functionally intact myeloid cells. These cells provide an immunity “boost” by preventing infection until the patient’s bone marrow can recover.
Clinical results to date demonstrate that NLA101 can enable rapid hematopoietic recovery, generating mature functional myeloid cells in patients with acquired pancytopenia (abnormally low levels of blood cells produced by the bone marrow) after high dose chemotherapy or chemotherapy/radiation. This product is not intended to persist long-term; rather, it is designed to provide a bridging source of functional cells until hematopoietic recovery or engraftment of the long-term donor is achieved — doing the job of a patient’s bone marrow until the patient’s bone marrow can recover.
In late 2016, Nohla completed a $43.5 million Series A financing round led by new investor ARCH Venture Partners and included participation from 5AM Ventures and existing investor, the Jagen Group. The Series A round brings the total financing obtained since the Company’s inception to $64.6 million.